M Sample code: D2; dimensionality K2; branching factor N50; size of each dataset iters 3; number of clustering iterations setup datasets, first column is the id dataset1 ones(N,1) randn(n,d dataset2 2*ones(N,1) 2*randn(N,2)repmat(-5 3,N 1 dataset3 3*ones(N,1).5*randn(N,2)repmat(5 3,N 1 data dataset1; dataset2; dataset3; build the. Hierarchy kmeanshierarchy(data, 2, D1, iters, k for test 1:16 generate a random point point rand*16-8 randn(1,D-1 plot the data cols 'bo rx gv hold off for i 1:size(data,1) hold on end hold off if (test1) title data Clusters (1Blue, 2Red, 3Green pause end hold. Set_id nn(1 line(point(1) nearest_neighbour(1 point(2) nearest_neighbour(2) title(sprintf Approx nearest neighbour: Set d set_id) pause end 1 piotr Indyk. Nearest neighbors in high-dimensional spaces. Handbook of Discrete and Computational geometry, chapter. Goodman and Joseph o'rourke, crc press, 2nd edition, 2004. Citeseer link 2 david Nistér and Henrik stewenius, Scalable recognition with a vocabulary Tree, cvpr'06 citeseer link mutual Information Thresholding The idea of selecting thresholds for data "adaptively" has been around for a long time.
How to find similarity index?
Image colour histogram extraction: getPatchHist. M Histogram comparison using the Bhattacharyya coefficient: compareHists. M Image colour spatiogram extraction: getPatchSpatiogram_fast. M Spatiogram comparison: compareSpatiograms_new_fast. M mpeg-7 Edge Orientation Histogram extraction: edgeOrientationHistogram. M (Note: code for histogram comparison can be used freshers with both colour histograms and edge orientation histograms) Sample code: - code to compare image histograms - read in database image im1 double(imread g read in query image im2 double(imread g both images are rgb colour. This code clusters the data into a hierarchy of clusters and does a depth-first search to find the approximate nearest-neighbour to the query point. This technique was used in 2 to match 128-dimensional sift descriptors to their visual words. M building a hierarchical tree of D-dimensional points: kmeanshierarchy. M Approximate nearest-neighbour using a hierarchical tree: kmeanshierarchy_findpoint.
References to the original papers given below. M, example usage: read in image 0000 of an image sequence im1 double(imread g read in image 0025 of an image sequence im2 double(imread g compute the difference image (Euclidian distance in rgb space) dif sqrt(sum(im1-im2).2,3 compute difference image histogram h, hc hist(makelinear(dif 256 perform. Etc source images (above) Thresholded difference images (from left to right rosin, kapur book and Otsu's method. Otsu, a threshold selection method from gray-level histogram, ieee trans on System Man Cybernetics 9 (1979. Wong, a new method for graylevel picture thresholding using the entropy of the histogram, computer Graphics and Image Processing 29 (1985. Rosin, Unimodal thresholding, pattern Recognition 34 (2001. 11, Image descriptors and Image similarity code to extract global descriptors for images and to compare these descriptors. Can be used for image retrieval, tracking, etc.
Zip, if you publish work which uses this code, please reference: ciarán oacute conaire, noel. O'connor and Alan. Smeaton, "Detector adaptation by maximising agreement between independent data sources ieee, international Workshop on Object Tracking and. Classification beyond the visible Spectrum 2007 (1) (2) (3) (1) Original image, (2) skin likelihood image and (3) Detected skin (using a threshold of zero). Layered Background Model, reference : Performance analysis and visualisation in tennis using a low-cost camera network, philip Kelly, ciarán ó conaire, david Monaghan, jogile kuklyte, damien Connaghan, juan diego pérez-moneo agapito, petros Daras, multimedia grand Challenge Track at acm multimedia 2010, 25-, firenze, italy. Pdf version, download Code : usage: model creation: n 5; number of layers t 20; rgb euclidian threshold (for determining if the pixel matches a layer).999; update rate.85; fraction of observed colour to account for in the background im imread. Adaptive image Thresholding, the following pieces of code implement the adaptive thresholding methods of Otsu, kapur and Rosin.
Earth, similarity, index - wikipedia
Performance analysis resume is also widely used with Denmark leading the way. The uk scored highest for agreement that government is on the right track and bim will be required for public sector work suggesting in the uk at least, the design community is open to the idea of the government taking the lead on bim. When it comes to information exchange, denmark leads the way in Industry foundation Classes (IFC) use with 65 of respondents having used them on projects compared to 55 in Japan, 49 in the uk and 45 in the czech Republic. Most respondents recognised that bim is a process that demands changes in workflow, practice and procedure. Only a small minority of non-users (less than a fifth) say they would rather not adopt bim. Encouragingly, those that have adopted bim rarely regret having done. Download the nbs international bim, report 2016 (.pdf,.2Mb).
Related reading, nbs international bim, report 2013, related nbs services. The nbs bim workflow is powered by a suite of tools that enable you to produce co-ordinated digital design information. Find out more about. Nbs services for bim projects. Matlab code for, skin Detection : Info: readme. Txt, full Matlab code and demo: skindetector.
Views about bim and the government's construction strategy. Bim adoption current and future trends. Attitudes towards bim, the difference bim makes to a practice. Specialist opinion pieces, who is it for? Uk construction professionals including architects, engineers, surveyors and contractors.
Manufacturers already embarking on bim or just starting to consider. Key findings, a complex picture different stages of development are evident in different countries but a broad similarity in views about bim is evident. Bim is seen as the future of project information in every country, more than three quarters of respondents agree. In all countries (bar the czech Republic) bim awareness is nearly universal (at over 90). The uk and Canada (surveyed in 2013, and again here) report increased numbers of bim users the uk has moved from 39 to 48, canada from 64 to 67, though we urge caution as the term may have different interpretations in different countries. Within five years all countries expect bim to be adopted by over 80 of design professionals with the next 12 months seeing the most rapid rate of adoption. Typically 90 of respondents are using bim to produce 3d visualisations. Clash detection is used by more than three quarters of bim users in all countries.
The, similarity, index (Originality, report )
Today we launch the nbs international bim. Report 2016 which serves to document a best complex and ever evolving picture with different stages of bim development evident in different countries, and the effects of governmental policy (such as the uk governments bim mandate) starting to be shredder felt. Running an international study has posed a range of methodological challenges. Aside from differences in language (with the associated problems of fidelity and grace in wording) there will, naturally, be national differences in understanding what bim is; differences rooted in different construction practices and regulatory frameworks. Therefore its best to read this report as a fascinating, but indicative, picture. Download the nbs international bim, report 2016 (.pdf,.2Mb interested in bim content from nbs? Register for our bim newsletter. What's in the report?
As of, the european Public Assessment Report (epar) for every newly-authorised medicine contains the orphan maintenance assessment report for all positive and negative comp opinions, as well as withdrawals. Pending orphan designation applications at time of marketing authorisation When an application for orphan designation is still pending at the time of marketing authorisation application, it is nevertheless possible for the medicinal product to be authorised as an orphan medicine provided that the orphan designation. However, in such cases, the eligibility to the centralised procedure (which precedes the marketing authorisation application) cannot be based on Article 3(1) and point 4 of the Annex to regulation (EC) no 726/2004. Similarly, a fee reduction will not be applicable, as this can only be considered if orphan designation has already been granted at the time of marketing authorisation application. See all ratings 17 ratings 14 ratings 16 ratings 23 ratings 22 ratings Tell us more. The second nbs international bim survey, carried out by nbs, working closely with the International Construction Information Society, provides a fascinating insight into bim adoption and maturity across five diverse countries. By running similar surveys (and sharing some key questions) weve been able to compare bim adoption across the uk, czech Republic, canada, japan and Denmark, shining a light on similarities and differences pretty in current attitudes and beliefs in the future of bim.
in Article 8(3) of the. Should the chmp conclude that the product which is the subject of the marketing authorisation application is similar to an authorised orphan medicinal product and none of the derogations apply, the chmp will adopt an opinion recommending the refusal of the granting of the marketing. Review of orphan designation at time of marketing authorisation If the sponsor of a medicine with an orphan designation submits a marketing authorisation application or an extension to an existing marketing authorisation, it should also submit a report on maintenance of the orphan designation. The sponsor's report includes data on: the current prevalence of the condition to be diagnosed, prevented or treated, or the potential return on investment; the current life-threatening or debilitating nature of the condition; the current existence of other methods for the diagnosis, prevention or treatment. A template is available for the report on the maintenance of the designation criteria: This enables the Agency to determine whether the medicine can maintain its status as an orphan medicine and benefit from market exclusivity. Market exclusivity is linked to the maintenance of the orphan designation when the medicine receives a marketing authorisation for the indication concerned. The comp reviews the maintenance of orphan designation based on the data available at the time and on the sponsor's report, and issues an orphan maintenance assessment report. The comp carries out its review independently of, but in parallel to the evaluation of the marketing authorisation application by the chmp. The comp adopts an opinion on the review of the orphan designation following the chmp positive opinion on the marketing authorisation application. Ema sends the comp opinion to the european Commission.
This legal requirement arises from Article 8(1) of the. Orphan Regulation (EC) no 141/1200. This provides that, where a marketing business authorisation in respect of an orphan medicinal product is granted, the Agency and the member States shall not, for a period of ten years, accept another marketing authorisation application, or grant a marketing authorisation or accept an application. Point 3 of Article 8 specifies that a marketing authorisation may be granted, for the same therapeutic indication, to a similar medicinal product if: the holder of the marketing authorisation for the original orphan medicinal product has given his consent to the second applicant, or;. Commission Regulation (EC) no 847/2000 defines the concept of similar medicinal product and clinical superiority. Article 3 defines similar medicinal product as a medicinal product containing a similar active substance or substances as contained in a currently authorised orphan medicinal product, and which is intended for the same therapeutic indication. It also defines similar active substance as an identical active substance, or an active substance with the same principal molecular structural features (but not necessarily all of the same molecular features) and which acts via the same mechanism. Based on the above mentioned definitions, the assessment of similarity between two medicinal products takes into consideration the following criteria: principal molecular structural features; mechanism of action; therapeutic indication. If significant differences exist within one or more of these criteria, the two products will not be considered as similar.
Similarity index and report
The european Medicines Agency (EMA) assesses whether a medicine continues to meet the criteria for maintaining its orphan shredder status in parallel with assessing an application for marketing authorisation. Sponsors may also need to submit an evaluation of orphan similarity. This enables ema to determine whether the medicine can maintain its status as an orphan medicine and benefit from market exclusivity. On this page, orphan similarity, in advance of marketing authorisation application, irrespective of whether the medicinal product in question has been designated as orphan or not, the applicant is advised to check the. Community register of orphan medicinal products for information on medicinal products designated as orphan which are under market exclusivity protection. If any of the designated orphan medicinal products has been granted a marketing authorisation in the european Union (eu and a period of market exclusivity is in force, a sponsor should attach to the marketing authorisation application a similarity report addressing the possible similarity between. Detailed information on submission of a similarity report is available.